Summary:
A 55-year-old female with standard risk AML in second CR received an allogenic transplant from an HLA-matched sibling, using a nonmyeloablative conditioning regimen (NMST). On day +139, she rejected her graft with autologous reconstitution. She received a second NMST from a different HLA-matched sibling with an identical conditioning regimen and immunosuppression. On day +110, she rejected the second graft, with autologous reconstitution with blasts. She received a third allograft from the first sibling with a myeloablative busulfan-based conditioning regimen. She is now day +270, in CR, with full donor chimerism.
Similar content being viewed by others
References
McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effect. Blood 2001; 97: 3390–3400.
Carella AM, Giralt S, Slavin S . Low intensity regimens with allogenic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologica 2000; 85: 304–313.
Spitzer TR . Nonmyeloablative allogenic stem cell transplant strategies and role of mixed chimerism. Oncologist 2000; 5: 215–223.
Champlin R, Khouri I, Anderlini P et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant 2001; 27: S13–S22.
Prigozhina TB, Gurevitch O, Morecki S et al. Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models. Exp Hematol 2002; 30: 89–96.
Feinstein L, Storb R . Reducing transplant toxicity. Curr Opin Hematol 2001; 8: 342–348.
Storb RF, Champlin R, Riddel SR et al. Non-myeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Program) 2001; 1: 375–391.
Lyle CF, Brenda MS, Ute H et al. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol 2003; 120: 281–288.
Shimoni A, Nagler A . Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations. Leukemia 2001; 15: 1967–1975.
Bornhäuser M, Deeg HJ, Radich L et al. Fludarabine and targeted busulfan as conditioning for patients with high-risk myeloid leukemia and myelodysplastic syndrome transplanted with hematopoietic stem cells from HLA-compatible related or unrelated donors. Bone Marrow Transplant 2002; 29: S58 (abstract O334).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Papineschi, F., Benedetti, E., Galimberti, S. et al. A myeloablative allograft after rejection of two consecutive nonmyeloablative transplants from two different HLA identical siblings. Bone Marrow Transplant 33, 659–660 (2004). https://doi.org/10.1038/sj.bmt.1704356
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704356
- Springer Nature Limited